At the U.S. Food and Drug Administration, we see these knowledge gaps as an opportunity to develop new ways of building the science to inform public health decisions. The FDA evaluates CBD just like any other substance we regulate, under a regulatory framework defined by law and with rigorous scientific evidence as a basis for both our regulatory approach and information we communicate. We’ve consistently communicated concerns and questions regarding the science, safety, and quality of many of these products based on currently available evidence. We still don’t have clear answers to important questions such as what adverse reactions may be associated with CBD products and what risks are associated with the long-term use of CBD products.
Better data in these areas are needed for the FDA and other public health agencies to make informed, science-based decisions that impact public health. We see an important public health opportunity in using novel sources of data and rigorous analytical methods to build a more robust base of scientific evidence on the safety profile and use of CBD products.
Inspirational Technologies “4 Hemp Club” promotes Hemp for Agriculture
As we continue to evaluate the regulatory frameworks that apply to certain cannabis-derived products that are intended for non-drug uses, including whether any new FDA regulations may be warranted, the FDA continues to work actively with drug developers through the investigational new drug, drug review, and drug approval processes. The FDA’s work in this area involves both meetings with drug developers to provide advice that is specific to the development of a proposed product, as well as the development of guidance documents on high-priority regulatory and scientific issues. For example, the FDA recently published a draft guidance “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research,” which, when final, will represent the agency’s current thinking on sources of cannabis, resources for information on quality considerations, and percent delta-9 THC calculation.
The FDA is evaluating comments submitted to the agency regarding this draft guidance. FDA’s CBD Product Sampling and Testing Activities Sampling and testing of marketed CBD products is another way that the FDA has gathered more information about the safety profile of these products. This is an important component of the FDA’s work because little is known about the amounts of CBD and various related cannabinoids, as well as the occurrence of toxic elements, pesticides, other possible chemical contaminants, and adulterants, that may be present in CBD products that are marketed to consumers.
The FDA made the results of such testing publicly available. The FDA also designed surveys of the market and currently is conducting a two-phase marketplace sampling and testing study.
The first phase involved a small sampling and analysis study (~200 samples) conducted by the agency. While the data collected so far are from a limited sample size and are insufficient to draw definitive conclusions regarding the prevalence of results in marketed products, general observations indicate fewer than half of the tested products which presented label claims contained CBD at concentrations within 20% of their claimed amount and some products contained the psychoactive, intoxicating cannabinoid THC. The FDA has recently published findings from this work.
We are currently working with a third party on conducting the second phase of the sampling plan that will involve a much larger sample set (1000-3000) that includes collection of CBD-containing products of various types. Additional Work is Needed to Build Data on CBD Use and Safety We are encouraged by the many groups that are interested in helping to develop better data on the use and safety of CBD products, but also note that existing efforts generally are not adequate to fill the outstanding knowledge gaps.
A Practical Framework for Robust, Collaborative CBD Data Projects to Inform Public Health Decisions Here, we describe a framework for the FDA’s work in the development of research projects that lay the methodological groundwork for high quality RWD science on the safety and use of CBD products. These research projects would be aimed at building upon currently existing independent state and national quality and safety monitoring efforts, observational study data models, and novel data sources to develop more robust capabilities and methods for CBD data collection and analysis.
Amy Abernethy, M.D., Ph.D.
We know from experience that collaborative projects with researchers across government, academia, and the private sector can stimulate rapid progress in the development of rigorous methods for collecting and analyzing RWD. Most recently, in the context of COVID-19, collaborative research projects between the FDA and outside data experts have focused on using RWD to improve analytical methods and inform the public health response to the pandemic. It is important to note that there are research questions for which RWD research projects are unlikely to substitute for certain types of traditional studies. We do not expect that analyses of observational data will substitute for other types of studies in certain contexts. For example, appropriately designed animal studies can address toxicological issues that are difficult to study in humans, such as chronic, developmental, and reproductive toxicity. However, we strongly believe that RWD, when collected and analyzed using rigorous methods, can be important for moving the science forward—including by aiding hypothesis generation and by refining the design of follow-up studies. For example, RWD may identify new potential adverse events or subpopulations of CBD users that should be the focus of follow-up studies. For CBD data collection and analysis efforts to have the maximum scientific impact, they should be designed to address the most significant practical and scientific challenges in this area.
Below, we highlight challenges in current capabilities for collecting and evaluating CBD-related data and point to a framework for the FDA’s development of research projects that leverage novel data sources and can form the foundation for additional research on the safety profile of CBD products. First, we describe principles that we believe should guide this work. Guiding principles for FDA’s work in this area include the following: Research projects should contribute, where possible, to the development of more sophisticated data infrastructure for understanding the safety and quality of CBD products. Research projects should yield information that helps us refine future studies—for example, by identifying potential adverse events or subpopulations that are most important to study further. Research projects should be designed with the goal of complementing existing work by other public health agencies, such as NIH and SAMHSA, as well as other stakeholders. States provide an important laboratory for novel data collection and analysis. The FDA projects should build on existing efforts at the state and national level to incorporate data from poison control centers, emergency departments, and other potential sources of information about adverse events related to CBD products.
What is the denominator of risk for adverse events in the population taking CBD?
What specific populations have the highest CBD exposures and what specific products are frequently used?
What other products, such as over-the-counter or prescription drugs, are used alongside CBD products?
Are there risks associated with interactions between CBD products and other products, beyond those that have already been identified and communicated by the FDA?
Data collection systems may not yet have specific codes that can precisely identify specific CBD products. Longitudinal studies (i.e., studies that provide data about the health of subjects over an extended period of time) are needed to understand long-term health effects of CBD use.
Evaluate approaches to link adverse event data with CBD product sampling and testing data. Collaborate on the development and evaluation of systems and methods, such as an open, opt-in registry for users of CBD, to gain a better understanding of safety outcomes of interest and incorporate data from other sources.
Evaluate the use of market-research data and other data sources that provide insights on the use of specific CBD products in different populations. Evaluate use of data linkage approaches to provide insights about safety risks that may appear across time while protecting the privacy of patients and consumers.
Evaluate the value of combining multiple research and data approaches to synthesize an aggregate view of CBD safety and quality across the market and across time. Evaluate which strategies are best for safety and quality monitoring for different types of CBD products. The use of novel data sources to complement other scientific data (e.g., toxicology studies) will be key to providing the foundational science needed to more fully understand the safety profile of products containing CBD.
We see significant promise in small, targeted projects that improve data methods in the near-term and point to future opportunities for collecting and analyzing data on CBD products and, potentially, other types of products in the future. Resources for You: FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) FDA and Cannabis: Research and Drug Approval Process Real-World Evidence Content current as of: 01/08/2021
Twenty percent of those aged 18-29 said they use CBD products, followed by 16 percent for ages 30-49, 11 percent for 50-64 years old and eight percent for those aged 65 years or older.
An average of 50 percent of Americans 18 years old or older said they don’t use CBD products, while 35 percent said they are not familiar with them.
Those aged 65 and older were the least familiar with CBD — 49 percent said they don’t know CBD products, compared to between 26-36 percent for the other age brackets.
Information is becoming a catalyst for CBD Use.
CBD products also seem to be more popular in the western U.S., with 21 percent of western respondents saying they used the products, compared to 11-13 percent for the rest of America.
Women are more likely to use CBD for anxiety than men (25 percent versus 14 percent), and men are more likely to use it for sleep (15 percent versus eight percent).
While CBD is marketed for many other purposes — such as for stress, muscle soreness, inflammation, for pets, and as skincare — five percent or less of respondents said they use it for those reasons.
The Federal Drug Administration (FDA) in the U.S. is still researching CBD’s uses and effectiveness.
Gallup concludes that while right now CBD is used most by younger people, older Americans stand to gain the most from the products as it can help them with the aches and pains that come with age.
Familiarity is fairly similar across societal groups, including by gender, party ID and most age categories. However, half of seniors vs. roughly two thirds of those under 65 know something about it.U.S. Adults’ Familiarity With CBD Oils.
Aware Americans Think CBD Is Beneficial
Nikki Fried as AG Commissioner has instituted Hemp Innovative
Those who are familiar with CBD oils credit the substance with having health benefits,
Confidence in CBD is also much greater the more people know about it.
The CBD-oil arena is extremely active right now, including medical research into its benefits, state legislation governing its sale, federal legislation encouraging its production and corporate investment growing in the business. According to Forbes, retail sales for CBD products were between $600 million and $2 billion last year but are expected to grow to $16 billion by 2025.
It’s a long list when you’re looking at the states it’s legal to grow hemp in 2019 — especially since only three states in the entire country didn’t make the cut.
That said, the restrictions placed by agricultural departments at the state level can severely impact the opportunities for hemp growers.
The 2018 Farming Bill paved the way for farmers to cash in on this incredible crop. However, it’s necessary to research the laws in your state before you get your hopes up. In addition to looking at the current regulations — with so many legislatures reviewing laws regarding industrial hemp growing — you’ll want to keep an eye on what’s potentially coming down the pipeline as well.
Industrial Hemp Farming – Where Is It Legal?
The industrial hemp farming act removed the plant from the list of controlled substances. The 1937 Marihuana Tax Act ban included hemp. However, farmers grew it in locations like Kentucky during the 1950s! It was also widely grown during World War II due to its many uses, which we discuss later on.
The Bill didn’t legalize CBD, nor did it guarantee the legal operation of an industrial hemp farm in every state. It made it clear that states had to develop a plan and submit it to the United States Department of Agriculture (USDA). Therefore, states are allowed to prohibit the growth of the plant.
The Farm Bill didn’t legalize CBD, nor did it guarantee the legal operation of an industrial hemp farm in every state.
At present, Idaho stands alone as the only American state to prohibit industrial hemp cultivation. Both Mississippi and South Dakota passed legislation in hemp’s favor in 2020. Incidentally, both states also legalized medical marijuana in November 2020. South Dakota went a step further. Recreational cannabis could be on sale in SD from 2022.
According to News America, Indiana is now one of the twenty-nine states with approved hemp licensing for commercial businesses.
Many states have submitted their plans for approval. Others have yet to do so and are happy to fall back on the Farm Bill regulations.
If you intend to grow hemp, there are plenty of considerations. Too many farmers are seduced by the potential riches that await them. Some estimates suggest one can earn $100,000 per acre. Of course, you must subtract a myriad of expenses. Nonetheless, this is less of an issue if you grow over 100 acres of high-quality hemp! In most states, up to 90% of all hemp is developed for the CBD industry. This is a shame because it is a crop with phenomenal potential.
What Are Industrial Hemp’s Uses?
The number #1 use of the crop is for the billion-dollar CBD market. It is understandable but limits the potential of this fantastic plant. If you think long and hard, you could develop a long list of useful industrial hemp products. Remember, this is a crop that once dominated the American landscape. Estimates vary, but it is believed that you can make approximately 25,000+ products from the plant!
The settlers at Jamestown in Virginia grew the crop in the 17th century; it was mandatory! Copies of the Bible were made with hemp paper, as was a draft of the Declaration of Independence. Humans used the crop for centuries with industrial hemp fiber, a particular favorite. In the early 1900s, hemp-derived cellulose was championed as a renewable and affordable raw material for plastics.
The key will be to get yourself situated in a state where it’s legal to grow hemp in 2019, and then get your hands on the right seeds and clones to ensure you have the highest quality crop come harvest time
The article also stated Indiana has started accepting hemp cultivation and processing licenses in November for the 2021 growing season. The state is offering one general hemp license and another one for agricultural hemp seed production. Applicants are also required to submit their personal address, GPS coordinates, where the hemp is located and a legal description of the property used for the hemp operation.
Many other states are also currently negotiating commercial hemp licensing plans with the U.S. Department of Agriculture as farmers increasingly seek to grow hemp for manufacturers seeking cannabidiol (CBD), cannabinol (CBN) and cannbigerol (CBG) for oils, lotions, foods and beverages. With more than 25,000 uses for hemp, farming hemp for textiles, insulation, pet bedding and more are increasing at an exponential rate.
(Source/Credit: News Americas Now)
One theory posits that hemp’s ability to replace synthetic materials such as plastic and nylon was a primary reason for its prohibition. You could make the argument that hemp was a threat to certain industries. DuPont produced neoprene in 1930, for example. However, the same company didn’t invent and patent nylon until the mid to late 1930s.
Incidentally, there is disagreement over the year that nylon was patented. Some sources suggest it was 1937, pbs.org suggests it was 1935, and other sources say it was 1938.
Regardless of the year, the anti-marijuana hysteria in the United States was already at a fever pitch by the mid-1930s. Perhaps the likes of the DuPont family were heavily involved in the Marihuana Tax Act of 1937, though we’ll never know.
What we do know is that the world was robbed of an incredible resource for decades. There are thousands of uses for hemp. Perhaps one of the most important is as a replacement for plastic. Hemp plastic is an eco-friendly alternative to the carbon-based plastics we use today. The hemp version is usually recyclable and biodegradable.
Is it a viable alternative for plastic, however? Can hemp even replaceplastic?
Inspirational Technologies is a Company Founded on the Ideals of Inspiring Collective Minds to Foster Health, Wellness & Sustainability
Thinking Outside The Pharmacy Box – CBD
You must be logged in to post a comment.